Antisense technology involves the use of short, synthetic strands of nucleic acids designed to bind to specific mRNA molecules. By binding to these mRNA molecules, antisense oligonucleotides (ASOs) can effectively inhibit the expression of genes associated with diseases. This technology has shown promise in treating a variety of genetic disorders, including those affecting neonates.
